Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (27)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Protheroe, A.
Right arrow Articles by Selby, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Protheroe, A.
Right arrow Articles by Selby, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 1999; 38: 1150-1152
© 1999 British Society for Rheumatology

Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma

A. Protheroe, J. C. W. Edwards1, A. Simmons, K. Maclennan and P. Selby

ICRF Cancer Medicine Research Unit, St James' University Hospital, Leeds and
1 Centre for Rheumatology, University College London, UK

Correspondence to: J. C. W. Edwards, UCL Centre for Rheumatology, 4th Floor, Arthur Stanley House, 40 Tottenham Street, London W1P 9PG, UK.

We describe a case involving a 53-yr-old male with a marginal zone B-cell lymphoma, associated with an IgM paraprotein and a rheumatoid factor-negative inflammatory polyarthropathy, treated with monoclonal anti-CD20 antibody. During the subsequent 12 weeks, evidence of synovitis reduced to a negligible level, despite no significant change in lymphoma bulk or paraprotein level. The relationship between the lymphoma and the arthropathy, and the likely mechanism of remission of the arthropathy, are discussed in the context of the potential value of anti-CD20 therapy in rheumatoid arthritis.

KEY WORDS: Anti-CD20, Lymphoma, Rheumatoid arthritis, B lymphocyte


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
T. Dorner and G. R. Burmester
No B cells--no active RA? Advances in B cell depletion in RA--repeated therapy under conditions of clinical practice
Rheumatology, April 1, 2007; 46(4): 563 - 564.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
K. M Summers and D. R Kockler
Rituximab Treatment of Refractory Rheumatoid Arthritis
Ann. Pharmacother., December 1, 2005; 39(12): 2091 - 2095.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
N Wilkinson, G Jackson, and J Gardner-Medwin
Biologic therapies for juvenile arthritis
Arch. Dis. Child., March 1, 2003; 88(3): 186 - 191.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. A. Mitchison and L. R. Wedderburn
B cells in autoimmunity
PNAS, August 1, 2000; 97(16): 8750 - 8751.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.